SIR,-It is with interest one reads the paper by Dr. A. M. W. Porter on depressive illness in a general practice (28 March, p. 773 The patient whose record is shown in Figure 1 was known to suffer from supine hypotension, having had two attacks when placed in the lithotomy position prior to artificial rupture of the membranes. When labour started she was turned on to her back so that the midwives could record the fetal heart rate. Although she disliked this position, she was able to tolerate it. An irregular fetal heart rate was reported so a scalp electrode was applied to the fetus. The record shows an irregular bradycardia lasting 30 minutes. The record in Figure 2 shows the change in fetal heart rate which was not accompanied by changes in fetal pH during a clinically more acute but shorter episode of supine hypotension than in the previous case. The patient, who was in the supine position, complained of feeling faint, became pale, and started to sweat. She recovered quickly as soon as she was turned on to her side. Figure 2 shows an episode of fetal tachycardia lasting three minutes followed by two minutes of profound bradycardia relieved by turning the patient on to her side.
Our experience of the beneficial effect to both mother and fetus of turning the mother on her side has encouraged us to try this simple expedient in all cases of fetal distress during labour. If by these authors, as such levels are unobtainable by similar dosages given by any other route, including intravenously. In the cases studied by us' 500mg. orallv gave maximum plasma levels of 1-2 Lg./ml.-that is, one tenth of those reported by Dr. Parkinson and others. Plasma levels were were determined by gas chromatography and were cross-checked by two independent laboratories, both with an extensive experience of plasma lignocaine estimations.
Furthermore, the lignocaine blood levels in excess of 10 ug./ml. reported by Dr. Parkinson would be expected to give rise to convulsions or even coma.
We also noticed transient symptoms of toxicity in volunteers receiving oral lignocaine. These occurred at much lower plasma levels than has been observed with intravenous administration. We suggested that in its passage through the liver immediately following absorption the lignocaine was partially metabolized and that the metabolite was responsible for the toxic effects. 
